Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer
Foluso O. Ademuyiwa, Ina Chen, Jingqin Luo, Mothaffar F. Rimawi, Ian S. Hagemann, Bryan Fisk, Gejae Jeffers, Zachary L. Skidmore, Anamika Basu, Megan M. Richters, X. Cynthia, Katherine N. Weilbaecher, Jennifer L. Davis, Rama Suresh, Lindsay L. Peterson, Ron Bose, Nusayba A. Bagegni, Caron Rigden, Ashley Frith, Timothy P. Rearden, Leonel F. Hernandez‐Aya, Anna Roshal, Katherine Clifton, Mateusz Opyrchal, Olaronke Akintola-Ogunremi, Byung Ha Lee, Sara Ferrando‐Martínez, S. Church, Meenakshi Anurag, Matthew J. Ellis, Feng Gao, William E. Gillanders, Obi L. Griffith, Malachi Griffith
Topics & Concepts
CarboplatinDocetaxelMedicineBreast cancerTriple-negative breast cancerOncologyInternal medicineChemotherapyGene signatureCancerImmunologyCisplatinBiologyGeneGene expressionBiochemistryBreast Cancer Treatment StudiesCancer Immunotherapy and BiomarkersHER2/EGFR in Cancer Research